1 December 2019 in Molecular Therapy Nucleic Acids
Recently, emerging evidence shows that dysregulation of circadian genes is closely associated with liver fibrosis. However, how dysregulation of circadian genes promotes liver fibrosis is unknown. In this study, we show that neuronal PAS domain protein 2 (NPAS2), one of the core circadian molecules that has been shown to promote hepatocarcinoma cell proliferation, significantly contributed to liver fibrogenesis. NPAS2 is upregulated in hepatic stellate cells (HSCs) after fibrogenic injury, which subsequently contributes to the activation of HSCs. Mechanistically, NPAS2 plays a profibrotic role via direct transcriptional activation of hairy and enhancer of split 1 (Hes1), a critical transcriptor of Notch signaling for the fibrogenesis process, in HSCs. Our findings demonstrate that NPAS2 plays a critical role in liver fibrosis through direct transcriptional activation of Hes1, indicating that NPAS2 may serve as an important therapeutic target to reverse the progression of liver fibrosis.
16 March 2020 in Liver International
18 July 2024 in Redox Report
Intestinal ischemia-reperfusion (I/R) injury is a multifactorial and complex clinical pathophysiological process. Current research indicates that the pathogenesis of intestinal I/R injury involves various mechanisms, including ferroptosis. Methane saline (MS) has been demonstrated to primarily exert anti-inflammatory and antioxidant effects in I/R injury. In this study, we mainly investigated the effect of MS on ferroptosis in intestinal I/R injury and determined its potential mechanism. In vivo and in vitro intestinal I/R injury models were established to validate the relationship between ferroptosis and intestinal I/R injury. MS treatment was applied to assess its impact on intestinal epithelial cell damage, intestinal barrier disruption, and ferroptosis. MS treatment led to a reduction in I/R-induced intestinal epithelial cell damage and intestinal barrier disruption. Moreover, similar to treatment with ferroptosis inhibitors, MS treatment reduced ferroptosis in I/R, as indicated by a decrease in the levels of intracellular pro-ferroptosis factors, an increase in the levels of anti-ferroptosis factors, and alleviation of mitochondrial damage. Additionally, the expression of Nrf2/HO-1 was significantly increased after MS treatment. However, the intestinal protective and ferroptosis inhibitory effects of MS were diminished after the use of M385 to inhibit Nrf2 in mice or si-Nrf2 in Caco-2 cells. We proved that intestinal I/R injury was mitigated by MS and that the underlying mechanism involved modulating the Nrf2/HO-1 signaling pathway to decrease ferroptosis. MS could be a promising treatment for intestinal I/R injury.
6 January 2026 in Cancer Cell International
Mitochondria are intracellular double-membrane-bound organelles that play a crucial role in maintaining redox homeostasis, disruptions of which are closely linked to oncogenesis. Recent investigations have identified SLC25A39 as a mitochondrial membrane transporter essential for the importation of glutathione (GSH) into mitochondria. However, the roles of SLC25A39 in human malignancies remain inadequately understood. Here, we observed a marked upregulation of SLC25A39, which correlates with poor prognostic outcomes in hepatocellular carcinoma (HCC). The silencing of SLC25A39 resulted in a reduction of HCC cell viability and proliferation through inducing ferroptosis via increasing mitochondrial ROS accumulation. In contrast, the overexpression of SLC25A39 enhanced survival and proliferation of HCC cells by promoting ferroptosis evasion through reducing mitochondrial ROS accumulation. Importantly, we discovered that the expression of SLC25A39 was notably increased in Sorafenib-resistant HCC cells, and silencing of SLC25A39 could sensitize HCC cells to ferroptotic cell death and augment the therapeutic efficacy of Sorafenib against HCC. Overall, our investigation provides comprehensive evidence that SLC25A39 is a critical regulator of ferroptosis evasion and proposes its potential as a therapeutic target to improve the effectiveness of Sorafenib in the treatment of HCC.
24 May 2026 in Pathology - Research and Practice